"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 32 | 7 | 39 |
| 1996 | 43 | 9 | 52 |
| 1997 | 34 | 10 | 44 |
| 1998 | 31 | 9 | 40 |
| 1999 | 25 | 10 | 35 |
| 2000 | 33 | 9 | 42 |
| 2001 | 18 | 9 | 27 |
| 2002 | 26 | 17 | 43 |
| 2003 | 29 | 24 | 53 |
| 2004 | 38 | 21 | 59 |
| 2005 | 31 | 24 | 55 |
| 2006 | 48 | 20 | 68 |
| 2007 | 34 | 32 | 66 |
| 2008 | 30 | 30 | 60 |
| 2009 | 44 | 36 | 80 |
| 2010 | 45 | 34 | 79 |
| 2011 | 53 | 33 | 86 |
| 2012 | 54 | 34 | 88 |
| 2013 | 57 | 20 | 77 |
| 2014 | 57 | 18 | 75 |
| 2015 | 76 | 17 | 93 |
| 2016 | 78 | 34 | 112 |
| 2017 | 70 | 30 | 100 |
| 2018 | 67 | 38 | 105 |
| 2019 | 71 | 31 | 102 |
| 2020 | 94 | 79 | 173 |
| 2021 | 81 | 90 | 171 |
| 2022 | 19 | 92 | 111 |
| 2023 | 10 | 83 | 93 |
| 2024 | 55 | 43 | 98 |
| 2025 | 5 | 6 | 11 |
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Timing of Influenza Antiviral Therapy and Risk of Death in Adults Hospitalized With Influenza-Associated Pneumonia, Influenza Hospitalization Surveillance Network (FluSurv-NET), 2012-2019. Clin Infect Dis. 2025 Feb 24; 80(2):461-468.
-
Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19. Clin Infect Dis. 2025 Feb 05; 80(1):63-71.
-
Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections. Life Sci Alliance. 2025 Apr; 8(4).
-
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy. J Viral Hepat. 2025 Feb; 32(2):e14056.
-
Zinc-finger PARP proteins ADP-ribosylate alphaviral proteins and are required for interferon-γ-mediated antiviral immunity. Sci Adv. 2025 Jan 31; 11(5):eadm6812.
-
COVID-19 clinical presentation, management, and epidemiology: a concise compendium. Front Public Health. 2025; 13:1498445.
-
Antiviral Mx proteins have an ancient origin and widespread distribution among eukaryotes. Proc Natl Acad Sci U S A. 2025 Jan 28; 122(4):e2416811122.
-
A single-site randomized controlled trial of partner navigation to HCV treatment for people who inject drugs: a study protocol for the You're Empowered for Treatment Initiation (YETI) partner trial. Trials. 2025 Jan 22; 26(1):26.
-
Optimization of a micro-scale air-liquid-interface model of human proximal airway epithelium for moderate throughput drug screening for SARS-CoV-2. Respir Res. 2025 Jan 16; 26(1):18.
-
Inpatient service utilization amongst infants diagnosed with Respiratory Syncytial Virus infection (RSV) in the United States. PLoS One. 2025; 20(1):e0317367.